Neuphoria Therapeutics (NEUP) Other Non-Current Liabilities (2021 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Other Non-Current Liabilities of $2.5 million for Q1 2026, up 67280.72% year-over-year from N/an in Q1 2025, and down 9.42% quarter-over-quarter from $2.7 million in Q4 2025.
Neuphoria Therapeutics (NEUP) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Other Non-Current Liabilities for 6 consecutive years, with $2.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 67280.72% year-over-year to $2.5 million; the TTM figure through Mar 2026 stood at $2.5 million (up 67280.72% YoY), while the FY2025 annual figure was $3.7 million, up 529.76% from the prior year.
- Other Non-Current Liabilities retreated to $2.5 million in Q1 2026 per NEUP's latest filing, from $2.7 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $8.1 million in Q3 2025 and bottomed at $3389.0 in Q4 2024.
- Historically, Other Non-Current Liabilities has averaged $1.8 million across 5 years, with a median of $301366.0 in 2023.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities surged 43.46% — and 2025, when it surged 235344.22%.
- Neuphoria Therapeutics' Other Non-Current Liabilities stood at $7492.2 in 2022, then soared by 99.81% to $14969.9 in 2023, then tumbled by 77.36% to $3389.0 in 2024, then surged by 79946.74% to $2.7 million in 2025, then declined by 9.42% to $2.5 million in 2026.
- Business Quant data shows NEUP's Other Non-Current Liabilities at $2.5 million in Q1 2026, $2.7 million in Q4 2025, and $8.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.04 Bn | 130.19 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.58 Bn | 77.59 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.34 Bn | 1.37 Bn |
| 4 | Moderna | 56.52 Bn | 51.38 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.04 Bn | 36.94 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.67 Bn | 27.36 Bn | 992.69 Mn |
| 7 | Insmed | 27.27 Bn | 26.11 Bn | 358.27 Mn |
| 8 | BioNTech SE | 27.14 Bn | 8.75 Bn | 668.28 Mn |
| 9 | Royalty Pharma | 27.12 Bn | 26.28 Bn | - |
| 10 | Neuphoria Therapeutics | 21.13 Mn | 1.69 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.46 Mn |
| Dec 31, 2025 | 2.71 Mn |
| Sep 30, 2025 | 8.09 Mn |
| Jun 30, 2025 | 3.70 Mn |
| Mar 31, 2025 | 3,647.00 |
| Dec 31, 2024 | 3,389.00 |
| Sep 30, 2024 | 3,437.00 |
| Jun 30, 2024 | 587,762.00 |
| Jun 30, 2023 | 14,969.94 |
| Jun 30, 2022 | 7,492.17 |
| Jun 30, 2021 | 5,222.51 |